Lucence presented clinical data at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago. The studies evaluate a liquid biopsy assay that combines circulating tumour DNA (ctDNA) and RNA (ctRNA) to improve cancer mutation detection.

• Technology: The assay uses proprietary amplicon-based next-generation sequencing (NGS) technology, AmpliMARK™, to identify mutations and gene fusions from a single blood sample.
• Clinical Data: Prospective multicentre data for metastatic non-small cell lung cancer (NSCLC) indicated that the integrated ctDNA and ctRNA approach increased the identification of clinically actionable variants.
• Diagnostic Utility: A pan-cancer analysis demonstrated that the inclusion of ctRNA captures gene fusions and molecular variants that are frequently undetected by ctDNA-only testing across multiple tumour types.

This summary is based on a press release issued by Lucence.